YR0096
Human PD-1 Monoclonal Antibody
Size
£355.00
- SKU:
- YR0096
- Additional Names:
- CD279|hPD-1|hPD-l|hSLE1|PD1|PDCD1|SLEB2
- Application:
- ELISA, FuncS, Neutralisation
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- Human PD-1
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- Q15116
- Synonyms:
- CD279;hPD-1;hPD-l;hSLE1;PD-1;PD1;programmed cell death 1 protein;programmed cell death protein 1;protein PD-1;SLEB2;systemic lupus erythematosus susceptibility 2
- Extra Details:
- Cemiplimab Biosimilar uses the same protein sequences as the therapeutic antibody cemiplimab.PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1).Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.Binding of the programmed death receptor (PD) ligands PD-L1 and PD-L2, to the PD-1 receptor inhibits T-cell proliferation and cytokine production. The upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway may contribute to the inhibition of active T-cell immune surveillance of tumors. Cemiplimab is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 ligands, causing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In mouse tumor models, blocking PD-1 activity resulted in decreased rates of tumor growth.
- Shipping Conditions:
- Blue Ice